GPR6 Inhibitors
GPR6 inhibitors are chemical compounds that selectively modulate the activity of the GPR6 receptor, a G protein-coupled receptor (GPCR) predominantly linked to signaling pathways involving cyclic adenosine monophosphate (cAMP). This receptor is primarily classified as an orphan receptor due to the limited identification of natural endogenous ligands. GPR6 is associated with the Gs protein family, which leads to the activation of adenylyl cyclase and subsequent increase in cAMP levels. Inhibitors of GPR6 work by blocking this activation, effectively reducing downstream signaling and modulating the physiological processes mediated by this receptor. The structure of GPR6 inhibitors often reflects their specificity toward the receptor, and they are designed to fit into the binding pockets of GPR6, preventing its interaction with activating ligands or G proteins.
The chemical structures of GPR6 inhibitors typically vary, encompassing both small molecules and larger, more complex structures. These inhibitors may possess lipophilic or hydrophilic characteristics depending on their molecular composition, and their interactions with GPR6 are often influenced by key structural features such as hydrogen bonding, hydrophobic interactions, or electrostatic forces. The identification and development of GPR6 inhibitors usually involve high-throughput screening methods or rational drug design techniques, aimed at enhancing the binding affinity and selectivity of the compounds. Structural modifications and functional group optimization are common approaches to improving their inhibitory activity and receptor specificity. Additionally, computational modeling is frequently used to predict the receptor-ligand interactions and optimize inhibitor design, allowing for more precise targeting of GPR6-related signaling pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
By elevating intracellular cAMP, Forskolin could initiate a cascade that results in the activation of protein kinase A (PKA). PKA may then phosphorylate transcription factors, leading to the suppression of GPR6 gene transcription. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
As a selective PDE4 inhibitor, Rolipram raises cAMP levels, which might trigger PKA to phosphorylate and deactivate transcription factors crucial for GPR6 synthesis, thereby reducing its expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 blocks MEK1/2 enzymes, which may prevent the phosphorylation of ERK1/2 kinases, leading to a decrease in transcriptional activators essential for GPR6 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
By inhibiting p38 MAPK, SB 203580 could deter the phosphorylation and activation of transcription factors that are essential for the initiation of GPR6 gene transcription, resulting in reduced expression of the receptor. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 hampers PI3K activity, potentially hindering downstream AKT phosphorylation. This interruption may lead to a decrease in transcriptional activity of genes, including the one encoding GPR6. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds and inhibits mTOR, which is a key kinase in controlling cell growth and protein synthesis. This inhibition might lead to a general decrease in mRNA translation, including that of GPR6. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
WY 14643 is an agonist of PPARα, and by activating this nuclear receptor, it could alter the transcriptional landscape and downregulate GPR6 gene expression as part of a broader alteration of metabolic genes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 may block the activation of MEK1/2, which is crucial for the downstream ERK1/2 pathway that can activate transcriptional programs. Disruption of this pathway may lead to decreased GPR6 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and by blocking JNK activity, it could prevent the activation of AP-1 transcription factor, a potential activator of GPR6 expression, thus leading to its downregulation. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW 9662 counteracts PPARγ activity, potentially leading to the suppression of transcriptional events that are necessary for the expression of GPR6. | ||||||